A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02053376
Recruitment Status : Active, not recruiting
First Posted : February 3, 2014
Last Update Posted : March 12, 2018
Information provided by (Responsible Party):
Nathan Bahary, MD, University of Pittsburgh

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : October 31, 2017
  Estimated Study Completion Date : August 31, 2018